Investigating Participation Patterns Among Stage IV Melanoma Patients
Understanding Patient Engagement Trends in Stage IV Melanoma Clinical Trials
1 other identifier
observational
500
1 country
1
Brief Summary
Clinical trials, specifically focused on stage IV melanoma, are crucial in assessing the safety and efficacy of new treatments for this disease. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation. The main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 16, 2023
CompletedFirst Posted
Study publicly available on registry
October 23, 2023
CompletedStudy Start
First participant enrolled
November 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2026
ExpectedOctober 23, 2023
October 1, 2023
1 year
October 16, 2023
October 16, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Number of stage IV melanoma patients who decide to enroll in a clinical research
3 months
Rate of stage IV melanoma patients who remain in clinical trial to trial completion
12 months
Eligibility Criteria
Patients with stage IV melanoma who are actively considering enrolling in a clinical study for said condition, but have not yet completed enrollment and randomization.
You may qualify if:
- Aged ≥ 18 years old
- Diagnosis of stage IV melanoma
- Able to comprehend the investigational nature of the protocol and provide informed consent
You may not qualify if:
- Female patients who are currently pregnant or nursing
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- Inability to perform regular electronic reporting
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Power Life Sciences
San Francisco, California, 94107, United States
Related Publications (3)
Scott JF, Conic RZ, Thompson CL, Gerstenblith MR, Bordeaux JS. Stage IV melanoma of unknown primary: A population-based study in the United States from 1973 to 2014. J Am Acad Dermatol. 2018 Aug;79(2):258-265.e4. doi: 10.1016/j.jaad.2018.03.021. Epub 2018 Mar 23.
PMID: 29580859BACKGROUNDWevers KP, Hoekstra HJ. Stage IV melanoma: completely resectable patients are scarce. Ann Surg Oncol. 2013 Jul;20(7):2352-6. doi: 10.1245/s10434-013-2881-1. Epub 2013 Feb 8.
PMID: 23392854BACKGROUNDLuen S, Wong SW, Mar V, Kelly JW, McLean C, McArthur GA, Haydon A. Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma: A Retrospective Study of Primary Tumor Characteristics. Am J Clin Oncol. 2018 Jan;41(1):90-94. doi: 10.1097/COC.0000000000000226.
PMID: 26325493BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Michael B Gill
Power Life Sciences Inc.
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CROSSOVER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 16, 2023
First Posted
October 23, 2023
Study Start
November 1, 2024
Primary Completion
November 1, 2025
Study Completion (Estimated)
November 1, 2026
Last Updated
October 23, 2023
Record last verified: 2023-10